Although the ALK inhibitor was able to significantly improve the clinical outcome of NSCLC patients with a RR of 60% and a PFS of 10 months, the emergence of resistance to crizotinib has been noticed as a challenge [14, 15]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.